Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA)
Heatwurx (NASDAQ:PCSA) versus Aquestive Therapeutics (NASDAQ:AQST) Critical Review
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
Why Is Processa Therapeutics (PCSA) Stock Up 90% Today?
What made Processa Pharmaceuticals stock nearly triple on Thursday?
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
Best Penny Stocks Under $1? 4 To Watch This Week
Processa Pharmaceuticals to Present at the ThinkEquity Conference
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference